Drug Trial Radar · NCT07498634
Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Sep 21, 2023
Primary completion
Aug 1, 2025
Study completion Nov 14, 2025
Sponsor
- Lead sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study. Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.
Conditions
- Phase III
Interventions
XKH004Drug
Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Is ASAS 40 achieved at W16?Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changzheng Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.